Get the Stockscreener App
86.22
0.55%
0.47
Pre-market:
86.22
Disc Medicine Inc stock is traded at $86.22, with a volume of 252.82K.
It is up +0.55% in the last 24 hours and up +30.48% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$85.75
Open:
$85.88
24h Volume:
252.82K
Relative Volume:
0.60
Market Cap:
$3.00B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-23.49
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
+0.69%
1M Performance:
+30.48%
6M Performance:
+74.46%
1Y Performance:
+92.37%
1-Day Range:
$84.52
$87.00
1-Week Range:
$83.95
$89.79
52-Week Range:
$30.82
$95.95
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
86.22 | 3.21B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
How sustainable is Disc Medicine Inc. stock dividend payoutQuarterly Market Review & Weekly Top Gainers Trade List - newser.com
Is Disc Medicine Inc. stock in correction or buying zoneGold Moves & Low Drawdown Trading Strategies - newser.com
Can Disc Medicine Inc. stock weather global recession2025 Key Lessons & Growth Focused Entry Reports - newser.com
Is Disc Medicine Inc. stock trading near support levelsDollar Strength & Entry and Exit Point Strategies - newser.com
How Disc Medicine Inc. stock performs in interest rate cyclesJuly 2025 Movers & Safe Entry Point Identification - newser.com
Why Disc Medicine Inc. stock is considered a top pickExit Point & Entry Point Confirmation Signals - newser.com
Will Disc Medicine Inc. stock maintain growth story2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Applying Wyckoff theory to Disc Medicine Inc. stockJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Morgan Stanley Issues Positive Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine stock reiterated Strong Buy at Raymond James on DISC-0974 potential - Investing.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Disc Medicine to Participate in Upcoming Investor Conferences - Enidnews.com
Disc Medicine (NASDAQ: IRON) to appear at Guggenheim, Stifel, Jefferies; live webcasts - Stock Titan
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What valuation multiples suggest for Disc Medicine Inc. stockEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
WilmerHale Advises Underwriters in $287.5 Million Public Offering of Disc Medicine - WilmerHale
IRON Stock: Morgan Stanley Raises Price Target to $115 | IRON St - GuruFocus
Morgan Stanley Raises Price Target on Disc Medicine to $115 From $90, Keeps Overweight Rating - MarketScreener
Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors - MSN
Chronic Kidney Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Jiangsu HengRui, Disc Medicine, 3SBio, Kind Pharma, Jiangsu Hansoh Pharm - Barchart.com
Disc Medicine (IRON): Evaluating Valuation After New Clinical Trial Plans and FDA Recognition Boost Pipeline Momentum - Yahoo Finance
Disc Medicine planning trial of iron overload treatment for sickle cell - Sickle Cell Disease News
Aug Chart Watch: Why Disc Medicine Inc. stock is considered a top pickQuarterly Earnings Summary & Daily Entry Point Trade Alerts - fcp.pa.gov.br
Top chart patterns to watch in Disc Medicine Inc.July 2025 Breakouts & Consistent Profit Focused Trading Strategies - newser.com
Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment - TipRanks
Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera - TipRanks
Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease - TipRanks
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? - sharewise.com
Disc Medicine’s Promising EPP Treatment Study: Key Updates and Market Impact - TipRanks
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):